The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle

Published on 10/04/2015 by admin

Filed under Surgery

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 4 (1 votes)

This article have been viewed 9404 times

Chapter 1 The Hypothalamic-Pituitary-Ovarian Axis and Control of the Menstrual Cycle

THE HYPOTHALAMUS

The hypothalamus forms the lower part of the lateral wall and the floor of the third ventricle, and weighs approximately 10 grams. The hypothalamus is typically divided into eight specific nuclei (consistently clustered groups of neurons) and three areas (less clustered, less distinctly demarcated neurons), as illustrated in Figure 1-1. From a reproductive standpoint, the most important of these are the arcuate nucleus and the preoptic area, the principal sites of GnRH-producing neurons.1 The arcuate nucleus is located in the medial basal hypothalamus and is the most proximal of all the hypothalamic nuclei to the optic chiasm and the pituitary stalk. The arcuate nucleus is also the site of dopamine-secreting neurons that function to inhibit pituitary prolactin secretion and neurons that secrete growth hormone-releasing hormone.

Neurosecretory cell products from the hypothalamus, including GnRH, are released into the portal system from the median eminence, a prominence in the pituitary stalk at the floor of the third ventricle. The portal system serves as the major route of communication between the hypothalamus and the anterior pituitary. In contrast, the pituitary stalk (infundibulum) directly connects neuronal cell bodies in the hypothalamus to the posterior pituitary. The pituitary stalk lies immediately posterior to the optic chiasm.

GnRH

GnRH is the primary hypothalamic regulator of pituitary reproductive function. Two human forms of GnRH (GnRH-I and GnRH-II) have been identified.2,3 Both are decapeptides and are the products of different genes. At least 20 other types of GnRH have been identified in fish, amphibians and protochordates, but none of these are believed to be present in humans.4,5

GnRH-I was first characterized and synthesized in 1971 by Andrew Schally and Roger Guillemin, an accomplishment for which both men ultimately received the Nobel prize.69 The structure of GnRH-I is common to all mammals, and its action is similar in males and females (Fig. 1-2). GnRH-I is synthesized from a much larger, 92-amino acid precursor peptide that contains GnRH-associated peptide.10 GnRH-I then travels along an axonal pathway called the tuberoinfundibular tract to the median eminence of the hypothalamus, where it is released into the portal circulation in a pulsatile fashion. The half-life of GnRH-I is very short (2 to 4 minutes) because it is rapidly cleaved between amino acids 5 and 6, 6 and 7, and 9 and 10. Because of its short half-life and rapid dilution in the peripheral circulation, serum GnRH-I levels are difficult to measure and do not correlate with pituitary action.

GnRH-I has three principal actions on anterior pituitary gonadotrophs: (1) synthesis and storage of gonadotropins, (2) movement of gonadotropins from the reserve pool to a point where they can be readily released, and (3) direct secretion of gonadotropins. GnRH-I pulses occur in response to intrinsic rhythmic activity within GnRH neurons in the arcuate nucleus. Pulsatile release of GnRH-I from the median eminence within a critical frequency and amplitude results in normal gonadotropin secretion.11,12 Continuous, rather than pulsatile, exposure to GnRH-I results in suppression of FSH and LH secretion and suppression of gonadotropin gene transcription.13,14

In the absence of gonadal feedback, the GnRH pulse frequency is approximately once per hour.15 During the menstrual cycle the frequency and amplitude of GnRH pulses vary in response to hypothalamic feedback (Table 1-2).16 In general, the follicular phase is characterized by high-frequency, low-amplitude pulses, and the luteal phase is characterized by lower-frequency, higher-amplitude pulses.17,18 However, considerable variability exists both between and within individuals.19 In humans, GnRH-I pulse frequency and amplitude are best approximated by measuring LH pulse frequency and amplitude.

Table 1-2 Menstrual Cycle Variation in LH Pulse Frequency and Amplitude

Cycle Phase Mean Frequency (minutes) Mean Amplitude (mIU/mL)
Early follicular 90 6.5
Mid-follicular 50 5
Late follicular 60–70 7
Early luteal 100 15
Mid-luteal 150 12
Late luteal 200 8

GnRH-II is most highly expressed outside of the brain, in tissues that include kidneys, bone marrow, and prostate. This is in contrast to GnRH-I, which is not expressed in high levels outside the brain. Although GnRH-II can induce release of both FSH and LH, it appears to have a wide array of physiologic functions outside the brain including regulation of cellular proliferation and mediation of ovarian and placental hormone secretion.20

Initial attempts in the mid-1990s to identify estrogen receptors in GnRH neurons were unsuccessful.21,22 However, subsequent use of more sophisticated techniques identified estrogen receptors α and β in the arcuate nucleus.2326 Both receptors mediate estrogen action on GnRH neurons in vivo.27,28 The GnRH gene contains a hormone response element for the estrogen–estrogen receptor complex.29 Transcription of GnRH-I and GnRH-II is differentially regulated by estrogen.30 The regulatory role of estradiol on GnRH is complex. Estrogen inhibits GnRH gene expression/biosynthesis, but secretion of GnRH may be increased, decreased, or unaffected.31,32

The activity of the hypothalamus is further modulated by nervous stimuli from higher brain centers. GnRH neurons exhibit many connections to each other and to other neurons. Some of the neurotransmitters that modulate GnRH secretion are outlined in Table 1-3. The effects of these neurotransmitters help explain the mechanism by which certain physical or clinical conditions may affect the menstrual cycle (Table 1-4).

Table 1-3 Neurotransmitter Effects on GnRH Release

Neurotransmitter Effect
Dopamine Inhibits GnRH release
Endorphin Inhibits GnRH release
Serotonin Inhibits GnRH release
Norepinephrine, epinephrine Stimulates GnRH release

Table 1-4 Mechanisms for Oligo/amenorrhea in Various Clinical Conditions

Hyperprolactinemia Elevated dopamine suppresses GnRH
Hypothyroidism Elevated TRH increases prolactin, which in turn increases dopamine which, then suppresses GnRH
Stress Increased corticotropin (ACTH) results in increased endorphins (both are derived from the same peptide precursor); endorphins suppress GnRH
Exercise Increased endorphins suppress GnRH

TRH = thyrotropin-releasing hormone; GnRH = gonadotropin-releasing hormone.

Cells that produce GnRH originate embryologically from the olfactory area.33 GnRH neurons, like olfactory epithelial cells of the nasal cavity, have cilia.34 During embryogenesis GnRH neurons migrate from the medial olfactory placode to the arcuate nucleus of the hypothalamus.35 The common origin of GnRH and olfactory neurons is demonstrated by Kallmann’s syndrome, where GnRH deficiency is associated with anosmia. Kallmann’s syndrome is believed to be caused by a variety of gene defects that affect neuronal cell migration.36

The common origin of GnRH and olfactory neurons is also suggestive of the relationship between pheromones and menstrual cyclicity. Pheromones are small airborne chemicals that when secreted externally by one individual may be perceived by other individuals of the same species, producing a change in sexual or social behavior. It is well recognized that women who work or live together often develop synchrony of their menstrual cycles.37 Moreover, it has been shown that odorless compounds from the axillae of cycling women can alter the cycle characteristics of recipient women.38 Presumably, these alterations occur through olfactory GnRH-mediated mechanisms.

The GnRH Receptor

The GnRH-I receptor is a G-protein receptor that utilizes inositol triphosphate and diacylglycerol as second messengers to stimulate protein kinase, release of calcium ions, and cyclic adenosine monophosphate (cAMP) activity. The GnRH-I receptor is encoded by a gene on chromosome 14q21.1 and is expressed in many parts of the body outside of the brain, including ovarian follicles and the placenta. In humans it appears that GnRH-II signaling occurs through the GnRH-I receptor.5 Although a GnRH-II receptor is present in many mammalian species, its functional capacity is limited due to a frame shift and a stop codon. GnRH receptors are regulated by many substances, including GnRH itself, inhibin, activin, estrogen, and progesterone.

Changes to the amino acid sequence of GnRH can extend its half-life to hours or days and can change its biologic activity from an agonist to an antagonist. All of the GnRH agonists currently available extend their half-life by substitutions at amino acid 6 and sometimes amino acid 10 of native GnRH (Table 1-5). Continuous activation of the GnRH receptor results in desensitization due to phosphorylation and conformational change of the receptor, uncoupling from G proteins, internalization of the receptor via endocytosis, and decreased receptor synthesis.39,40 On administration all GnRH agonists increase gonadotropin secretion (the flare effect). However, after 7 to 14 days GnRH receptor desensitization occurs and pituitary suppression is achieved.

In contrast, GnRH antagonists directly inhibit gonadotropin secretion. Structurally, GnRH antagonists are characterized by multiple amino acid substitutions to the natural GnRH decapeptide. The commercially available GnRH antagonists cetrorelix and ganirelix have large amino acid additions to position 1 of native GnRH. GnRH antagonists compete for and occupy pituitary GnRH receptors, thus competitively blocking endogenous GnRH–GnRH receptor binding. In contrast to GnRH agonists, there is no flare effect with GnRH antagonists. Because receptor loss does not occur, a constant supply of antagonist is necessary to ensure that all GnRH receptors are continuously occupied. Thus, the therapeutic dosage range for antagonists is typically higher than that for agonists (mg versus μg).

THE PITUITARY

The pituitary gland measures approximately 15 × 10 × 6 mm and weighs approximately 500 to 900 mg. The pituitary gland lies immediately beneath the third ventricle and just above the sphenoidal sinus in a bony cavity called the sella turcica (Turkish saddle). It consists of anterior and posterior lobes, each having different embryologic origins, functions, and control mechanisms (Fig. 1-3).

The secretion of pituitary hormones is controlled primarily by the hypothalamus. However, the activity of the hypothalamus and pituitary are modulated by nervous stimuli from higher brain centers and feedback from circulating hormones. There is no direct nervous connection between the hypothalamus and the anterior pituitary gland. Instead, communication occurs via the hypothalamic-pituitary portal system.

The arterial blood supply of the pituitary is derived from branches of the internal carotid artery. The anterior pituitary gland is the most richly vascularized of all mammalian tissues. The blood supply of the anterior pituitary comes from the superior hypophyseal artery. The superior hypophyseal artery forms a capillary network in the median eminence of the hypothalamus that recombines in long portal veins draining down the pituitary stalk to the anterior pituitary, where they break up into another capillary network. The blood supply of the posterior pituitary (neurohypophysis) comes from the middle and inferior hypophyseal arteries. Veins from these arteries drain into the cavernous sinuses, from which they ultimately reach the petrosal sinuses and then the jugular veins.

The posterior pituitary is best understood as a continuation of the hypothalamus. The posterior pituitary is a direct downgrowth of nervous tissue from the hypothalamus through the pituitary stalk. The posterior pituitary is composed of glial tissue and axonal termini that secrete oxytocin and arginine vasopressin (AVP, also known as antidiuretic hormone). Oxytocin is synthesized in the paraventricular nucleus of the hypothalamus, whereas AVP is synthesized in the supraoptic nucleus, just above the arcuate nucleus. Oxytocin and AVP pass down the length of the pituitary stalk and are stored in terminal parts of axons in the posterior pituitary. Both oxytocin and AVP consist of nine amino acid residues (nonapeptides). Release of oxytocin and AVP is controlled directly by nervous impulses passing down the axons from the hypothalamus.

The Anterior Pituitary

The anterior pituitary arises from an epithelial upgrowth from the roof of the primitive oral cavity (Rathke’s pouch). The anterior pituitary wraps around the posterior pituitary and constitutes two thirds of the volume of the pituitary gland. The portion of Rathke’s pouch in direct contact with the posterior pituitary develops less extensively than the rest of the anterior pituitary and is termed the pars intermedia.

The major cell types of the anterior pituitary are outlined in Table 1-6. The anterior pituitary is a classic endocrine gland in that it is composed of secretory cells of epithelial origin supported by connective tissue rich in blood and lymphatic capillaries. In accordance with their active synthetic function the endocrine cells are characterized by prominent nuclei and prolific mitochondria, endoplasmic reticulum, Golgi bodies, and secretory vesicles. Synthesis of gonadotropins takes place in the rough endoplasmic reticulum, after which the hormones are packaged within the Golgi apparatus and stored as secretory granules. In response to GnRH the secretory granules are extruded from the cell membrane. The endothelial lining of capillary sinusoids is fenestrated, facilitating the passage of pituitary hormones into the sinusoids.

Gonadotropins

The anterior pituitary secretes two hormones that stimulate the growth and activity of the gonads, FSH and LH. These glycoprotein hormones, termed gonadotropins, work in conjunction to stimulate secretion of steroid hormones from the ovary.

FSH

FSH is a glycoprotein with a molecular weight of approximately 29,000 daltons. It consists of both an α and β subunit. The α subunit consists of 92 amino acids stabilized by 5 disulfide bonds and is identical to the α subunit of LH, thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (hCG). The β subunit contains 118 amino acids and 5 sialic acid residues. Neither subunit has any intrinsic biologic activity by itself.

The sialic acid content of FSH, LH, TSH, and hCG varies, and these differences are largely responsible for variations in half-life of the glycoprotein hormones. The liver is the major site of clearance for gonadotropins. Sialic acid prevents hepatic clearance; thus, the greater the sialic acid content, the longer the half-life.41 hCG, with 20 sialic acid residues, has the longest half-life (about 24 hours), whereas LH (1 to 2 sialic acid residues) has the shortest half-life (20 to 30 minutes). Addition of sialic acid residues in urinary-derived commercially available gonadotropins (e.g., hMG) is responsible for their longer half-life (30 hours).

In gonadotrophs of the anterior pituitary, GnRH signaling leads to transcription of the α and β subunits for both FSH and LH. The GnRH-dependent availability of the β subunits is the rate-limiting step in gonadotropin synthesis. Although both FSH and LH require GnRH stimulation, synthesis of the FSH β subunit also requires the presence of activin.42,43

Follicle-stimulating hormone plays a crucial role in follicle recruitment and selection of the dominant follicle. FSH has a trophic effect on granulosa cells in antral follicles, including the induction of aromatase activity, inhibin synthesis, and expression of LH receptors. A certain amount of FSH (the FSH threshold) is required to induce these changes in a given follicle. FSH must then remain above that threshold for folliculogenesis to continue.

In the normal menstrual cycle serum concentrations of FSH begin to rise a few days before the onset of menstruation. FSH levels plateau in the midfollicular phase and decline in the late follicular phase in response to the rise in estrogen and inhibin B. This decline contributes to the dominance of selected follicles over others. FSH levels then peak briefly during the ovulatory gonadotropin surge, after which they decline to their nadir in the luteal phase.

Opioid Modulation of Pituitary Hormones

Opioids (i.e., endogenous opiates) are natural occurring sedative narcotics produced in the brain whose structure and function are similar to opium. Opioids include enkephalins, endorphins, and dynorphins; they modulate every pituitary hormone by acting on the hypothalamus. An important action of opioids is to inhibit gonadotropin secretion by suppressing GnRH release.45

Opioid tone is an important regulator of menstrual cyclicity.4649 Endorphins are at a nadir in the early follicular phase (menstruation) and gradually rise to peak levels in the luteal phase in response to the rise in estrogen and progesterone. It is believed that opioids mediate the negative feedback of ovarian steroids on gonadotropin release, particularly in the luteal phase.50

Endogenous opioids appear to play a central role in hypothalamic amenorrhea. Treatment of women suffering from this condition with an opioid receptor antagonist (e.g., naltrexone) results in the return to ovulatory menstrual patterns and even conception in some cases.51,52 Women with stress-related amenorrhea demonstrate increased hypothalamic corticotropin-releasing hormone and pituitary corticotropin, which manifests as hypercortisolism.53 The corticotropin precursor peptide, pro-opiomelanocortin, is also the precursor for endorphin synthesis. It is hypothesized that stress-related amenorrhea is the result of GnRH inhibition secondary to increased production of endogenous opioids. Opioids also rise during exercise (“runners’ high”), and this may contribute to hypothalamic amenorrhea in athletes.54,55

Ovarian Peptide Hormone Feedback on Gonadotropin Secretion

The ovary secrets two polypeptide hormones that inhibit or stimulate FSH secretion by the anterior pituitary. Inhibin and activin act as opposing nonsteroidal gonadal hormones that regulate FSH synthesis and secretion by the pituitary. They also have paracrine effects within the ovary, where they modulate follicle growth and steroidogenesis. Follistatin is a binding protein that modulates the effects of activin but not inhibin.

Inhibin and Activin

Inhibin and activin are members of the transforming growth factor-β (TGF-β) superfamily of ligands, which includes müllerian inhibiting substance (MIS; see Chapter 2). Like the gonadotropins, inhibin and activin are comprised of two subunits. Inhibin is comprised of an α and β subunit and has been isolated in two forms containing different β subunits, Inhibin-A and Inhibin-B. Activin is comprised of two beta subunits identical to those found in inhibin.

Inhibin is secreted by granulosa cells in response to FSH.56 However, mRNA for inhibin has also been found in pituitary gonadotrophs. Inhibin selectively inhibits FSH but not LH secretion.57 Thus, a negative feedback loop is created where FSH stimulates inhibin and in turn inhibin suppresses FSH.

Inhibin B is predominantly secreted in the follicular phase of the menstrual cycle, whereas inhibin A is predominantly secreted in the luteal phase.58 Peak levels of inhibin B in the follicular phase are in the range of 50 to 100 pg/mL. Peak levels of inhibin A in the luteal phase are between 40 and 60 pg/mL.

Activin is also secreted by granulosa cells. Activin augments the secretion of FSH by the pituitary by enhancing GnRH receptor formation. Activin is also required for synthesis of the FSH β subunit.

In the ovary, activin augments FSH action and stimulates production of follistatin by a paracrine effect. These effects of activin are blocked by both inhibin and follistatin. With increased GnRH stimulation, activin is increasingly antagonized by inhibin and bound by follistatin.

OVARIAN STEROIDOGENESIS DURING THE MENSTRUAL CYCLE

Ovarian steroidogenesis during the menstrual cycle occurs in granulosa and theca cells (Table 1-7 and Fig. 1-4). Before ovulation, theca cells are separated from granulosa cells in the same follicle by a basal membrane. Thus, granulosa cells of preovulatory follicles do not have a blood supply. However, at the time of the LH surge the preovulatory follicle undergoes luteinization with disappearance of the basal membrane and capillary invasion of the granulosa cells. Theca cells become theca-lutein cells, and granulosa cells become granulosa-lutein cells.

Table 1-7 Site of Synthesis of Major Steroidogenic Products of the Ovary

Cell Type Major Steroid Hormone Products
Theca cells Androgens (androstenedione, DHEA, testosterone)*
Granulosa cells Estrogens (estradiol, estrone)
Theca-lutein cells Progestogens (progesterone, 17-hydroxyprogesterone)**
Granulosa-lutein cells Estrogens (estradiol, estrone)

* Mostly via Δ5 pathway

** Via Δ4 pathway

If pregnancy does not occur, the lifespan of the corpus luteum is fixed at approximately 14 days. After 12 to 14 days luteolysis and apoptosis are initiated. The corpus luteum involutes, and menstruation occurs. Ovarian steroidogenesis then shifts to a new cohort of follicles with their granulosa and theca cells.

Two-Cell Theory

The two-cell, two-gonadotropin theory of ovarian steroidogenesis holds that follicular estrogen/androgen production is compartmentalized.59 Ovarian theca cells produce androgens in response to LH. These androgens may then be aromatized to estrogens in granulosa cells appropriately stimulated by FSH. FSH receptors are present only on granulosa cells, and early in the follicular phase LH receptors are present only on theca cells.60 The enzyme P450c17 (17-hydroxylase and 17,20-lyase) is only present in theca cells. Thus, only theca cells have the ability to convert 21-carbon steroids to 19-carbon steroids. In contrast, aromatase is only present in granulosa cells. Thus, in the ovary only granulosa cells have the ability to aromatize androgens to estrogens (Table 1-8 and Fig. 1-5). Supporting evidence for the two-cell theory includes the fact that women with hypogonadotropic hypogonadism may develop follicles in response to treatment with recombinant FSH, but do not significantly elevate androgen or estrogen levels unless LH is added to the stimulation regimen.61

Table 1-8 Location Specificity of P450c17 and Aromatase

Enzyme Location Function
P450c17 Theca cells only Converts 21-carbon steroids (progesterone/pregnenolone) to 19-carbon steroids (androstenedione, DHEA)
Aromatase Granulosa cells only Converts 19-carbon steroids (androstenedione/testosterone) to 18-carbon steroids (estrone, estradiol)

Estrogens

Estrogens are 18-carbon steroids that include estradiol (i.e., 17β-estradiol), estrone, and estriol. The most potent estrogen, estradiol, is predominantly secreted by the ovary. Estrone, which is one twelfth as potent as estradiol, is also secreted by the ovary. However, the principal source of estrone is from peripheral conversion from androstenedione. Estriol, which is one eightieth as potent as estradiol, is the principal estrogen formed by the placenta during pregnancy. Estriol is also formed by metabolism of estradiol and estrone by the liver and is the most abundant estrogen found in urine.

Estrogen is largely bound to carrier proteins in serum. Approximately 60% of estradiol is bound to albumin, 38% is bound to sex hormone-binding globulin (SHBG), and 2% to 3% is free. It had previously been thought that only the free hormone was active and could enter cells, but recent evidence suggests that hormone transport and hormone availability may be more complex.62

Progesterone

Progesterone, a 21-carbon steroid, is the principle secretory steroid of the corpus luteum. Progesterone is responsible for the induction of secretory changes that prepare estrogen-primed endometrium for implantation. If implantation occurs, continued progesterone production is necessary for maintenance of the pregnancy.

The release of FSH and LH require the continuous pulsatile release of GnRH. The coordinated secretion of FSH and LH control follicle growth, ovulation, and maintenance of the corpus luteum. The release of FSH and LH is both positively and negatively influenced by estrogen and progesterone. Whether estrogen and progesterone stimulate or inhibit gonadotropin release depends on the quantity and duration of exposure to the steroid.

At high concentrations progesterone inhibits both FSH and LH secretion by negative feedback on both the hypothalamus and pituitary.65 Progesterone also slows the GnRH pulse generator; hence the decline in GnRH pulse frequency in the luteal phase. However, at low concentrations, and only after previous exposure to estrogen, progesterone stimulates LH release.66

Androgens

Ovarian theca cells secrete a variety of androgens (i.e., 19-carbon steroids), including androstenedione, testosterone, and dehydroepiandrosterone (DHEA). Androstenedione is the principal androgen secreted by ovarian theca cells. Theca cells also possess the enzyme 17β-hydroxysteroid dehydrogenase, which may convert androstenedione to testosterone. In premenopausal women, at least 60% of circulating testosterone is derived from the ovary, by either this conversion or direct secretion.

Androstenedione and testosterone can then be aromatized to estrogens in granulosa cells under the influence of FSH. Androstenedione can also be converted to estrone or testosterone in peripheral tissues. Unlike testosterone and dihydrotestosterone, androstenedione does not have high affinity for the androgen receptor.

Side chain cleavage of cholesterol to pregnenolone is the starting point and rate-limiting step in steroidogenesis. In the ovary cholesterol side chain cleavage is regulated by LH. Low-density lipoprotein (LDL) cholesterol is the principal source of cholesterol for steroidogenesis in the human ovary.67 Increased cAMP production due to LH stimulation of adenylate cyclase increases transcription of LDL receptor mRNA and LDL uptake. cAMP-activated steroidogenic acute regulatory protein then increases the intracellular transport of cholesterol to the inner mitochondrial membrane, where side chain cleavage occurs.68

In the preovulatory follicle the preferred pathway for androgen/estrogen synthesis involves conversion of pregnenolone to 17-hydroxypregnenolone, the so-called Δ5 pathway (see Fig. 1-4). Ovarian theca cells have the enzymatic capability to convert pregnenolone to androgens, but lack the ability to aromatize androstenedione or testosterone into estrogens. Only granulosa cells, under the influence of FSH, can aromatize androgens to estrogens. In contrast to the preovulatory follicle, the corpus luteum prefers the Δ4 pathway, the initial conversion of pregnenolone to progesterone.

CONTROL OF THE MENSTRUAL CYCLE

Normal menstrual cycles, termed eumenorrhea, normally range in length between 24 to 35 days, with menstrual bleeding lasting 3 to 7 days. The average amount of blood loss is approximately 30 mL.70 Heavy, prolonged, or irregular menses are referred to as abnormal uterine bleeding and are considered in length in Chapter 21.

Normal menstrual cycles result from a relatively precise interaction of the hypothalamus, pituitary, and ovaries. Under the influence of pituitary gonadotropins, the ovary undergoes cyclic changes providing for the development and release of a mature oocyte and production of ovarian hormones that prepare the endometrial lining for implantation. LH stimulates androgen production in theca cells; FSH promotes follicle development and aromatization of androgens to estrogens in granulosa cells (see Fig. 1-5). In turn, estrogens lead to proliferation of the endometrial lining and the induction of endometrial receptors for both estrogen and progesterone.71

To understand the menstrual cycle it is helpful to divide it into four phases: the follicular phase, the ovulatory phase, the luteal phase, and the luteal–follicular transition. We concentrate on changes in pituitary and ovarian hormones and the effects that these hormones have on the hypothalamus, pituitary, and ovary.

Follicular Phase

The purpose of the follicular phase is to develop a single mature follicle to release a mature oocyte at ovulation. The presence of sufficient FSH also leads to expression of LH receptors on mature granulosa cells of preovulatory follicles. Thus, in the late follicular phase LH can sustain follicular endocrine activity, even in the absence of FSH.72 The follicular phase is variable in duration, but the other three phases are relatively constant, averaging 14 ± 2 days.

Gonadotropins

FSH levels rise in the early follicular phase due to the lack of negative inhibition from estradiol and inhibin (Fig. 1-6). FSH stimulates follicle growth and estrogen production.73 Through binding of FSH to its receptor, granulosa cells in developing follicles attain the ability to aromatize androstenedione to estrone and testosterone to estradiol. Importantly, receptors for FSH are not detected on granulosa cells until the preantral stage.74 Moreover, both in vitro and in vivo administration of FSH to granulosa cells can cause upregulation or downregulation of granulosa cell FSH receptors.75 Without functional FSH follicle growth and ovarian estrogen production cannot occur.76

The steady decline in FSH beginning in the midfollicular phase serves to inhibit development of all but the dominant follicle. The dominant follicle remains dependent on FSH and must complete its development in spite of declining FSH levels. Because it has the largest cohort of granulosa cells, it has the largest cohort of FSH receptors and thus is able to grow in the face of insufficient FSH for smaller follicles.

Luteinizing hormone levels are stable in the first half of the follicular phase. However, in the second half LH levels rise in response to positive feedback from increasing estrogen.

Ovarian Hormones

Estradiol levels rise as the dominant follicle emerges. FSH and estrogen synergistically exert a mitogenic effect on granulosa cells, stimulating their proliferation. This in turn increases the FSH receptor content of the follicle, enhancing the ability of the follicle to respond to FSH and produce estrogen. Curiously, not every granulosa cell must express FSH receptors to respond to the gonadotropin signal. Gap junctions between cells allow cells with receptors to transmit protein kinase activation to their neighbors.77

Within the follicular fluid of follicles greater than 8 mm in diameter, the concentration of FSH, estradiol, and progesterone are all extremely high. Within smaller antral follicles, androgens predominate in the follicular fluid. The role of androgens in the follicle is dose-dependent. At low levels androgens provide a substrate for aromatization. However, at higher levels androgens are converted in granulosa cells by 5α-reductase to more active forms such as dihydrotestosterone (DHT) that cannot be aromatized to estrogens.78,79 Granulosa cells have androgen receptors.80 Activation of granulosa cell androgen receptors inhibits aromatase activity and also inhibits FSH induction of granulosa LH receptors.81 Follicles exposed to excessive androgens eventually become atretic.82,83 In contrast, follicles with the highest estrogen-to-androgen ratios and the highest estrogen concentrations are most likely to contain a competent oocyte.84

Rising estradiol levels have a dual role for the follicle. Within the follicle, estradiol promotes granulosa cell growth, aromatization of androgens to estrogens, and, in combination with FSH, induction of development of LH receptors on granulosa cells. However, outside the follicle rising serum estradiol levels have an inhibitory effect on FSH secretion. The resulting decline in FSH levels in the mid- to late follicular phase limits aromatase activity in smaller follicles, leading to higher androgen levels and follicular atresia. Indeed, a reduction in granulosa cell expression of FSH receptors is one of the first signs of follicular atresia.

Inhibin B levels begin to rise almost immediately after the rise in FSH levels. By the midfollicular phase the rise in estradiol and inhibin B levels causes FSH levels to decline. Inhibin B levels peak approximately 4 days after the FSH peak.47 In the late follicular phase inhibin B levels fall, mirroring the decline in FSH levels.

Progesterone and inhibin A levels are low throughout most of the follicular phase, but both begin to rise in the days immediately preceding ovulation. The rise in progesterone in the late follicular phase mirrors the rise in LH.

Ovulatory Phase

The ovulatory phase begins with the midcycle LH surge, which disrupts contacts between granulosa cells and the cumulus oophorus (specialized granulosa cells surrounding the oocyte), causing the oocyte to detach from the follicle wall. The LH surge also induces the resumption of meiosis within the oocyte and release of the oocyte–cumulus complex from the follicle (ovulation).

GnRH

GnRH plays a supporting role for the midcycle gonadotropin surge, but it does not trigger the surge.85 There is no change in GnRH pulse frequency during the midcycle gonadotropin surge.86 Rather, ovarian steroid feedback to the primed anterior pituitary triggers the LH surge.87 Whereas estrogen inhibits the secretion of pituitary gonadotropins, it facilitates their synthesis and storage. Estrogen also increases the expression of GnRH receptors.88,89 Thus, in the mid- to late follicular phase each pulse of GnRH is met with a greater gonadotropin response.90,91 When the estradiol level in the circulation meets a critical level for a sufficiently long period of time, the inhibitory action of estradiol on LH secretion changes to a stimulatory one. The LH surge is accompanied by a surge of GnRH in both portal and peripheral blood.92 However, as demonstrated by women with hypogonadotropic hypogonadism treated with a pulsatile GnRH pump, ovulation and pregnancy may occur in the absence of any change in GnRH pulse frequency or amplitude.93 Moreover, the LH surge ends before there is a decline in the GnRH signal.94

Gonadotropins

Both FSH and LH levels peak just before ovulation. The initiation of the gonadotropin surge is dependent on attaining serum estradiol levels of at least 200 pg/mL for at least 2 days.95 In natural cycles this level of estradiol is typically not attained until the dominant follicle reaches a mean diameter of 15 mm.96

During the gonadotropin surge serum LH levels increase tenfold over a period of 2 to 3 days, while FSH levels increase fourfold. Within the dominant follicle the LH surge induces detachment of the oocyte–cumulus complex from the follicle wall. The release of the oocyte–cumulus complex from its follicular wall attachments is accompanied by the resumption of meiosis and release of the first polar body.

The LH surge also induces luteinization of the periovulatory follicle. Luteinization refers to functional and morphologic changes within the theca–granulosa cell complex associated with accumulation of a yellow pigment called lutein. The function of the FSH surge is less clearly known, but it is believed to ensure an adequate number of LH receptors on the granulosa layer and to increase production of plasminogen activator, thus increasing the concentration of the proteolytic enzyme plasmin.

Ovulation typically occurs from mature follicles 34 to 36 hours after the onset of the LH surge.97 The peak of LH and FSH occurs 10 to 12 hours before ovulation.98 The LH surge usually lasts 48 to 50 hours and must be maintained for at least 14 hours for full maturation of the oocyte to occur.99 The mechanism that turns off the LH surge is unknown. It may simply reflect the depletion in pituitary LH content.

Ovarian Hormones

Just prior to ovulation the follicle becomes vascularized.100 Angiogenesis is mediated by LH and a variety of other factors, including vascular endothelial growth factor.101103 Prostaglandins reach peak levels in the follicular fluid.104 Proteolytic enzymes digest collagen in the follicular wall, resulting in distensibility and thinning just before ovulation.105 Progesterone rises in the follicular fluid. FSH, LH, and progesterone all serve to increase the activity of proteolytic enzymes. There is a rapid increase in follicular fluid volume, but due to increased elasticity there is little to no change in intrafollicular pressure. Finally, a protrusion (stigma) appears on the follicular wall, and it is at this site that ovulation ultimately occurs.

Interestingly, spontaneous lueteinization occurs in the absence of LH when granulosa cells are removed from follicles and cultured in vitro. Similarly, cumulus-enclosed oocytes removed from developing follicles before the LH surge will spontaneously resume meiosis.106,107 These findings have led to speculation that substances functioning as oocyte maturation inhibitors or luteinization inhibitors must exist within each follicle. Further support for this hypothesis lies in the fact that cumulus cells lack LH receptors.

Estradiol levels fall beginning with the onset of the LH surge. Progesterone and inhibin A levels continue to rise at the time of ovulation. Inhibin B levels surge at the time of ovulation. Luteinization of the follicle begins.

Luteal Phase

The luteal phase is the time when the ovary secrets progesterone, resulting in endometrial receptivity for embryo implantation. LH receptors on granulosa cells result in luteinization, driving the postovulatory follicle to become a corpus luteum. Granulosa cells become granulosa-lutein cells with their own blood supply and begin secretion of both estrogen and progesterone. Release of large amounts of progesterone from the corpus luteum results in secretory endometrial changes and the final development of endometrial receptivity.

Ovarian Hormones

After ovulation granulosa and theca cells of the dominant follicle are luteinized. Luteinization involves both chemical and morphologic changes. Granulosa and theca cells hypertrophy and increase steroidogenesis. Moreover, breakdown of the basal membrane that previously separated granulosa and theca cells leads to capillary invasion around granulosa-lutein cells.

Granulosa-lutein cells can now make progesterone directly from LDL via side chain cleavage and 3β-hydroxysteroid dehydrogenase. Levels of mRNA for side chain cleavage and 3β-hydroxysteroid dehydrogenase are maximal at the time of ovulation and in the early luteal phase.111 The induction of LDL receptor expression in granulosa cells occurs in response to the LH surge and is an early feature of luteinization.112 Progesterone secretion correlates with the number of LH receptors and adenylate cyclase activity.113 Progesterone levels peak during the midluteal phase.

Granulosa-lutein cells cannot make estrogens directly from cholesterol because they lack the enzyme P450c17. However, granulosa-lutein cells continue to be able to aromatize theca-lutein produced androgens to estrogens, and estrogen levels remain high throughout most of the luteal phase.

In granulosa-lutein cells inhibin production switches from inhibin B to inhibin A. Thus inhibin B levels decline to their nadir during the luteal phase, whereas inhibin A levels reach their peak. Secretion of inhibin A by granulosa-lutein cells is controlled by LH.114 Inhibin A, like inhibin B, suppresses FSH levels.115

Luteal–Follicular Transition

As the luteal phase continues, progesterone inhibits LH release via a negative feedback loop on the anterior pituitary. During the luteal–follicular transition, subsequent decline in LH causes the corpus luteum to involute unless the corpus luteum is rescued by production of hCG from an implanting embryo.

Involution of the corpus luteum leads to a fall in both estrogen and progesterone production. The endometrium can no longer be maintained and menstruation occurs. The fall of estrogen production then reactivates FSH secretion, initiating a new cycle of follicular development with estrogen secretion and renewed proliferation of the endometrial lining.

Gonadotropins

FSH and LH levels rise from their nadir due to the decline in negative feedback from estradiol and inhibin and the rise in activin.116 The rise in FSH initiates recruitment of gonadotropin-responsive follicles for the next menstrual cycle. This recruitment of antral follicles actually begins at least 2 days before the onset of menstrual bleeding. In fact, an increase in FSH bioactivity can be measured back to the midluteal phase.117 During the luteal–follicular transition both inhibin A and B levels are at a nadir.118 In contrast, activin levels begin to increase in the late luteal phase and peak at the time of menstruation.119 Activin plays an important role as gonadotropin responses to GnRH require the presence of activin.43

Ovarian Hormones

In the absence of pregnancy corpus luteum function declines approximately 10 days after ovulation. The exact mechanisms for luteolysis are unclear. Luteolysis involves apoptosis and expression of matrix metalloproteinases.120,121 Luteolysis may also be mediated by nitric oxide.122 Nitric oxide induces apoptosis in the human corpus luteum.123 One of the final signs of luteolysis is ovarian production of prostaglandin F, which inhibits luteal steroidogenesis. Thus, unless the corpus luteum is rescued by the hCG of pregnancy, estrogen, progesterone, and inhibin levels fall as the luteal–follicular transition occurs.

PEARLS

REFERENCES

1 Rance NE, Young WS3rd, McMullen NT. Topography of neurons expressing luteinizing hormone-releasing hormone gene transcripts in the human hypothalamus and basal forebrain. J Comp Neurol. 1994;339:573-586.

2 White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA. 1998;95:305-309.

3 Cheng CK, Leung PCK. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II and their receptors in humans. Endocr Rev. 2005;26:283-306.

4 Morgan K, Millar RP. Evolution of GnRH ligand precursors and GnRH receptors in protochordate and vertebrate species. Gen Comp Endocrinol. 2004;139:191-197.

5 Millar RP, Lu ZL, Pawson AJ, et al. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25:235-275.

6 Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun. 1971;43:393-399.

7 Schally AV, Arimura A, Kastin AJ, et al. Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173:1036-1038.

8 Arimura A, Matsuo H, Baba Y, Schally AV. Ovulation induced by synthetic luteinizing hormone-releasing hormone in the hamster. Science. 1971;174:511-512.

9 Amoss M, Burgus R, Blackwell R, et al. Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of ovine origin. Biochem Biophys Res Commun. 1971;44:205-210.

10 Nikolics K, Mason AJ, Szonyi E, et al. A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone. Nature. 1985;316:511-517.

11 Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53-88.

12 Mais V, Kazer RR, Cetel NS, et al. The dependency of folliculogenesis and corpus luteum function on pulsatile gonadotropin secretion in cycling women using a gonadotropin-releasing hormone antagonist as a probe. J Clin Endocrinol Metab. 1986;62:1250-1255.

13 Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypopthalamic gonadotropin-releasing hormone. Science. 1978;202:631-633.

14 Haisenleder DJ, Dalkin AC, Ortolano GA, et al. A pulsatile gonadotropin-releasing hormone stimulus is required to increase transcription of the gonadotropin subunit genes: Evidence for differential regulation of transcription by pulse frequency in vivo. Endocrinology. 1991;128:509-517.

15 Marshall JC, Dalkin AC, Haisenleder DJ, et al. Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog Horm Res. 1991;47:155-189.

16 Reame N, Sauder SE, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion during the human menstrual cycle: Evidence for altered frequency of gonadotropin-releasing hormone secretion. J Clin Endocrinol Metab. 1984;59:328-337.

17 Filicori M, Santoro N, Merriam GR, Crowley WFJr. Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J Clin Endocrinol Metab. 1986;62:1136-1144.

18 Hall JE, Schoenfeld DA, Martin KA, Crowley WFJr. Hypothalamic gonadotropin-releasing hormone secretion and follicle-stimulating hormone dynamics during the luteal-follicular transition. J Clin Endocrinol Metab. 1992;74:600-607.

19 Veldhuis JD, Evans WS, Johnson ML, et al. Physiological properties of the luteinizing hormone pulse signal: Impact of intensive and extended venous sampling paradigms on its characterization in healthy men and women. J Clin Endocrinol Metab. 1986;62:881-891.

20 Kauffman AS. Emerging functions of gonadotropin-releasing hormone II in mammalian physiology and behaviour. J Neuroendocrinol. 2004;16:794-806.

21 Sullivan KA, Witkin JW, Ferin M, Silverman AJ. Gonadotropin-releasing hormone neurons in the rhesus macaque are not immunoreactive for the estrogen receptor. Brain Res. 1995;685:198-200.

22 Herbison AE, Horvath TL, Naftolin F, Leranth C. Distribution of estrogen receptor-immunoreactive cells in monkey hypothalamus: Relationship to neurones containing luteinizing hormone-releasing hormone and tyrosine hydroxylase. Neuroendocrinology. 1995;61:1-10.

23 Kallo I, Butler JA, Barkovics-Kallo M, et al. Oestrogen receptor beta-immunoreactivity in gonadotropin releasing hormone-expressing neurones: Regulation by oestrogen. J Neuroendocrinol. 2001;13:741-748.

24 Hrabovszky E, Steinhauser A, Barabas K, et al. Estrogen receptor-beta immunoreactivity in luteinizing hormone-releasing hormone neurons of the rat brain. Endocrinology. 2001;142:3261-3264.

25 Hrabovszky E, Shughrue PJ, Merchenthaler I, et al. Detection of estrogen receptor-beta messenger ribonucleic acid and 125I-estrogen binding sites in luteinizing hormone-releasing hormone neurons of the rat brain. Endocrinology. 2000;141:3506-3509.

26 Skynner MJ, Sim JA, Herbison AE. Detection of estrogen receptor alpha and beta messenger ribonucleic acids in adult gonadotropin-releasing hormone neurons. Endocrinology. 1999;140:5195-5201.

27 Abraham IM, Han SK, Todman MG, et al. Estrogen receptor beta mediates rapid estrogen actions on gonadotropin-releasing hormone neurons in vivo. J Neurosci. 2003;23:5771-5777.

28 Dorling AA, Todman MG, Korach KS, Herbison AE. Critical role for estrogen receptor alpha in negative feedback regulation of gonadotropin-releasing hormone mRNA expression in the female mouse. Neuroendocrinology. 2003;78:204-209.

29 Radovick S, Ticknor CM, Nakayama Y, et al. Evidence for direct estrogen regulation of the human gonadotropin-releasing hormone gene. J Clin Invest. 1991;88:1649-1655.

30 Chen A, Zi K, Laskar-Levy O, Koch Y. The transcription of the hGnRH-I and hGnRH-II genes in human neuronal cells is differentially regulated by estrogen. J Mol Neurosci. 2002;18:67-76.

31 Matagne V, Lebrethon MC, Gerard A, Bourguignon JP. In vitro paradigms for the study of GnRH neuron function and estrogen effects. Ann NY Acad Sci. 2003;1007:129-142.

32 Krajewski SJ, Abel TW, Voytko ML, Rance NE. Ovarian steroids differentially modulate the gene expression of gonadotropin-releasing hormone neuronal subtypes in the ovariectomized cynomolgus monkey. J Clin Endocrinol Metab. 2003;88:655-662.

33 Schwanzel-Fukuda M, Pfaff DW. Origin of luteinizing hormone-releasing hormone neurons. Nature. 1989;338:161-164.

34 Jennes L, Stumpf WE, Sheedy ME. Ultrastructural characterization of gonadotropin-releasing hormone (GnRH)-producing neurons. J Comp Neurol. 1985;232:534-547.

35 Silverman AJ, Jhamandas J, Renaud LP. Localization of luteinizing hormone-releasing hormone (LHRH) neurons that project to the median eminence. J Neurosci. 1987;7:2312-2319.

36 Waldstreicher J, Seminara SB, Jameson JL, et al. The genetic and clinical heterogeneity of gonadotropin-releasing hormone deficiency in the human. J Clin Endocrinol Metab. 1996;81:4388-4395.

37 McClintock MK. Menstrual synchorony and suppression. Nature. 1971;229:244-245.

38 Stern K, McClintock MK. Regulation of ovulation by human pheromones. Nature. 1998;392:177-179.

39 Suarez-Quian CA, Wynn PC, Catt KJ. Receptor-mediated endocytosis of GnRH analogs: Differential processing of gold-labeled agonist and antagonist derivatives. J Steroid Biochem. 1986;24:183-192.

40 Schvartz I, Hazum E. Internalization and recycling of receptor-bound gonadotropin-releasing hormone agonist in pituitary gonadotropes. J Biol Chem. 1987;262:17046-17050.

41 Morell AG, Gregoriadis G, Scheinberg IH, et al. The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem. 1971;246:1461-1467.

42 Weiss J, Guendner MJ, Halvorson LM, Jameson JL. Transcriptional activation of the follicle-stimulating hormone beta-subunit gene by activin. Endocrinology. 1995;136:1885-1891.

43 Besecke LM, Guendner MJ, Schneyer AL, et al. Gonadotropin-releasing hormone regulates follicle-stimulating hormone-beta gene expression through an activin/follistatin autocrine or paracrine loop. Endocrinology. 1996;137:3667-3673.

44 Richards JS, Hedin L. Molecular aspects of hormone action in ovarian follicular development, ovulation, and luteinization. Annu Rev Physiol. 1988;50:441-463.

45 Goodman RL, Parfitt DB, Evans NP, et al. Endogenous opioid peptides control the amplitude and shape of gonadotropin-releasing hormone pulses in the ewe. Endocrinology. 1995;136:2412-2420.

46 Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotrophin secretion in humans. Hum Reprod. 1993;8(Suppl 2):151-153.

47 Whisnant SC, Havern RL, Goodman RL. Endogenous opioid suppression of luteinizing hormone pulse frequency and amplitude in the ewe: Hypothalamic sites of action. Neuroendocrinology. 1991;54:587-593.

48 Genazzani AR, Petraglia F. Opioid control of luteinizing hormone secretion in humans. J Steroid Biochem. 1989;33:751-755.

49 Ferin M. The role of endogenous opioid peptides in the regulation of the menstrual cycle. J Steroid Biochem. 1989;33(4B):683-685.

50 Maruncic M, Casper RF. The effect of luteal phase estrogen antagonism on luteinizing hormone pulsatility and luteal function in women. J Clin Endocrinol Metab. 1987;64:148-152.

51 Wildt L, Sir-Petermann T, Leyendecker G, et al. Opiate antagonist treatment of ovarian failure. Hum Reprod. 1993;8(Suppl 2):168-174.

52 Wildt L, Leyendecker G, Sir-Petermann T, Waibel-Treber S. Treatment with naltrexone in hypothalamic ovarian failure: Induction of ovulation and pregnancy. Hum Reprod. 1993;8:350-358.

53 Suh BY, Liu JH, Berga SL, et al. Hypercortisolism in patients with functional hypothalamic-amenorrhea. J Clin Endocrinol Metab. 1988;66:733-739.

54 De Cree C. Endogenous opioid peptides in the control of the normal menstrual cycle and their possible role in athletic menstrual irregularities. Obstet Gynecol Surv. 1989;44:720-732.

55 Harber VJ, Sutton JR. Endorphins and exercise. Sports Med. 1984;1:154-171.

56 Bicsak TA, Tucker EM, Cappel S, et al. Hormonal regulation of granulosa cell inhibin biosynthesis. Endocrinology. 1986;119:2711-2719.

57 Rivier C, Rivier J, Vale W. Inhibin-mediated feedback control of follicle-stimulating hormone secretion in the female rat. Science. 1986;234:205-208.

58 Groome NP, Illingworth PJ, O’Brien M, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:1401-1405.

59 McNatty KP, Smith DM, Makris A, et al. The intraovarian sites of androgen and estrogen formation in women with normal and hyperandrogenic ovaries as judged by in vitro experiments. J Clin Endocrinol Metab. 1980;50:755-763.

60 Kobayashi M, Nakano R, Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the “two-cell, two-gonadotrophin” hypothesis of steroidogenesis in the human ovary. J Endocrinol. 1990;126:483-488.

61 Schoot DC, Coelingh Bennink HJ, Mannaerts BM, et al. Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotropin deficiency. J Clin Endocrinol Metab. 1992;74:1471-1473.

62 Mendel CM. The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl. 1992;13:107-116.

63 Miller CD, Miller WL. Transcriptional repression of the ovine follicle-stimulating hormone-beta gene by 17 beta-estradiol. Endocrinology. 1996;137:3437-3446.

64 Baratta M, West LA, Turzillo AM, Nett TM. Activin modulates differential effects of estradiol on synthesis and secretion of follicle-stimulating hormone in ovine pituitary cells. Biol Reprod. 2001;64:714-719.

65 Wildt L, Hutchison JS, Marshall G, et al. On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. Endocrinology. 1981;109:1293-1294.

66 Liu JH, Yen SS. Induction of midcycle gonadotropin surge by ovarian steroids in women: A critical evaluation. J Clin Endocrinol Metab. 1983;57:797-802.

67 Carr BR, MacDonald PC, Simpson ER. The role of lipoproteins in the regulation of progesterone secretion by the human corpus luteum. Fertil Steril. 1982;38:303-311.

68 Clark BJ, Soo SC, Caron KM, et al. Hormonal and developmental regulation of the steroidogenic acute regulatory protein. Mol Endocrinol. 1995;9:1346-1355.

69 Hu YC, Wang PH, Yeh S, et al. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA. 2004;101:11209-11214.

70 Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss—a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand. 1966;45:320-351.

71 Lessey BA, Killam AP, Metzger DA, et al. Immunohistochemical analysis of human uterine estrogen and progesterone receptors throughout the menstrual cycle. J Clin Endocrinol Metab. 1988;67:334-340.

72 Sullivan MW, Stewart-Akers A, Krasnow JS, et al. Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): A role for LH in the final stages of follicular maturation. J Clin Endocrinol Metab. 1999;84:228-232.

73 Yong EL, Baird DT, Hillier SG. Mediation of gonadotrophin-stimulated growth and differentiation of human granulosa cells by adenosine-3′,5′-monophosphate: One molecule, two messages. Clin Endocrinol (Oxf). 1992;37:51-58.

74 Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. 1997;82:3748-3751.

75 LaPolt PS, Tilly JL, Aihara T, et al. Gonadotropin-induced up- and down-regulation of ovarian follicle-stimulating hormone (FSH) receptor gene expression in immature rats: Effects of pregnant mare’s serum gonadotropin, human chorionic gonadotropin, and recombinant FSH. Endocrinology. 1992;130:1289-1295.

76 Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. Nat Genet. 1993;5:83-86.

77 Fletcher WH, Greenan JR. Receptor mediated action without receptor occupancy. Endocrinology. 1985;116:1660-1662.

78 McNatty KP, Makris A, Reinhold VN, et al. Metabolism of androstenedione by human ovarian tissues in vitro with particular reference to reductase and aromatase activity. Steroids. 1979;34:429-443.

79 Hillier SG, van den Boogaard AM, Reichert LEJr, van Hall EV. Intraovarian sex steroid hormone interactions and the regulation of follicular maturation: Aromatization of androgens by human granulosa cells in vitro. J Clin Endocrinol Metab. 1980;50:640-647.

80 Hild-Petito S, West NB, Brenner RM, Stouffer RL. Localization of androgen receptor in the follicle and corpus luteum of the primate ovary during the menstrual cycle. Biol Reprod. 1991;44:561-568.

81 Jia XC, Kessel B, Welsh THJr, Hsueh AJ. Androgen inhibition of follicle-stimulating hormone-stimulated luteinizing hormone receptor formation in cultured rat granulosa cells. Endocrinology. 1985;117:13-22.

82 Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: A review of structure/function relationships. Endocr Rev. 1985;6:371-399.

83 Chabab A, Hedon B, Arnal F, et al. Follicular steroids in relation to oocyte development and human ovarian stimulation protocols. Hum Reprod. 1986;1:449-454.

84 Andersen CY. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab. 1993;77:1227-1234.

85 Knobil E, Plant TM, Wildt L, et al. Control of the rhesus monkey menstrual cycle: Permissive role of hypothalamic gonadotropin-releasing hormone. Science. 1980;207:1371-1373.

86 Adams JM, Taylor AE, Schoenfeld DA, et al. The midcycle gonadotropin surge in normal women occurs in the face of an unchanging gonadotropin-releasing hormone pulse frequency. J Clin Endocrinol Metab. 1994;79:858-864.

87 Nakai Y, Plant TM, Hess DL, et al. On the sites of the negative and positive feedback actions of estradiol in the control of gonadotropin secretion in the rhesus monkey. Endocrinology. 1978;102:1008-1014.

88 Gregg DW, Nett TM. Direct effects of estradiol-17 β on the number of gonadotropin-releasing hormone receptors in the ovine pituitary. Biol Reprod. 1989;40:288-293.

89 Bauer-Dantoin AC, Weiss J, Jameson JL. Roles of estrogen, progesterone, and gonadotropin-releasing hormone (GnRH) in the control of pituitary GnRH receptor gene expression at the time of the preovulatory gonadotropin surges. Endocrinology. 1995;136:1014-1019.

90 Adams TE, Norman RL, Spies HG. Gonadotropin-releasing hormone receptor binding and pituitary responsiveness in estradiol-primed monkeys. Science. 1981;213:1388-1390.

91 Menon M, Peegel H, Katta V. Estradiol potentiation of gonadotropin-releasing hormone responsiveness in the anterior pituitary is mediated by an increase in gonadotropin-releasing hormone receptors. Am J Obstet Gynecol. 1985;151:534-540.

92 Xia L, Van Vugt D, Alston EJ, et al. A surge of gonadotropin-releasing hormone accompanies the estradiol-induced gonadotropin surge in the rhesus monkey. Endocrinology. 1992;131:2812-2820.

93 Leyendecker G, Wildt L, Hansmann M. Pregnancies following chronic intermittent (pulsatile) administration of Gn-RH by means of a portable pump (“Zyklomat”)—a new approach to the treatment of infertility in hypothalamic amenorrhea. J Clin Endocrinol Metab. 1980;51:1214-1216.

94 Caraty A, Antoine C, Delaleu B, et al. Nature and bioactivity of gonadotropin-releasing hormone (GnRH) secreted during the GnRH surge. Endocrinology. 1995;136:3452-3460.

95 Young JR, Jaffe RB. Strength–duration characteristics of estrogen effects on gonadotropin response to gonadotropin-releasing hormone in women. II. Effects of varying concentrations of estradiol. J Clin Endocrinol Metab. 1976;42:432-442.

96 Cahill DJ, Wardle PG, Harlow CR, Hull MG. Onset of the preovulatory luteinizing hormone surge: Diurnal timing and critical follicular prerequisites. Fertil Steril. 1998;70:56-59.

97 Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: A reevaluation. J Clin Endocrinol Metab. 1983;57:792-796.

98 Pauerstein CJ, Eddy CA, Croxatto HD, et al. Temporal relationships of estrogen, progesterone, and luteinizing hormone levels to ovulation in women and infrahuman primates. Am J Obstet Gynecol. 1978;130:876-886.

99 Zelinski-Wooten MB, Hutchison JS, Chandrasekher YA, et al. Administration of human luteinizing hormone (hLH) to macaques after follicular development: Further titration of LH surge requirements for ovulatory changes in primate follicles. J Clin Endocrinol Metab. 1992;75:502-507.

100 McClure N, Macpherson AM, Healy DL, et al. An immunohistochemical study of the vascularization of the human graafian follicle. Hum Reprod. 1994;9:1401-1405.

101 Wulff C, Wilson H, Wiegand SJ, et al. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology. 2002;143:2797-2807.

102 Wulff C, Wilson H, Largue P, et al. Angiogenesis in the human corpus luteum: Localization and changes in angiopoietins, tie-2, and vascular endothelial growth factor messenger ribonucleic acid. J Clin Endocrinol Metab. 2000;85:4302-4309.

103 Dickson SE, Fraser HM. Inhibition of early luteal angiogenesis by gonadotropin-releasing hormone antagonist treatment in the primate. J Clin Endocrinol Metab. 2000;85:2339-2344.

104 Lumsden MA, Kelly RW, Templeton AA, et al. Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. J Reprod Fertil. 1986;77:119-124.

105 Yoshimura Y, Santulli R, Atlas SJ, et al. The effects of proteolytic enzymes on in vitro ovulation in the rabbit. Am J Obstet Gynecol. 1987;157:468-475.

106 Edwards RG. Maturation in vitro of human ovarian oocytes. Lancet. 1965;2(7419):926-929.

107 Edwards RG. Maturation in vitro of mouse, sheep, cow, pig, rhesus monkey and human ovarian oocytes. Nature. 1965;208:349-351.

108 Hutchison JS, Zeleznik AJ. The rhesus monkey corpus luteum is dependent on pituitary gonadotropin secretion throughout the luteal phase of the menstrual cycle. Endocrinology. 1984;115:1780-1786.

109 Filicori M, Butler JP, Crowley WFJr. Neuroendocrine regulation of the corpus luteum in the human. Evidence for pulsatile progesterone secretion. J Clin Invest. 1984;73:1638-1647.

110 Sheehan KL, Casper RF, Yen SS. Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: A model for fertility control. Science. 1982;215:170-172.

111 Bassett SG, Little-Ihrig LL, Mason JI, Zeleznik AJ. Expression of messenger ribonucleic acids that encode for 3 β-hydroxysteroid dehydrogenase and cholesterol side-chain cleavage enzyme throughout the luteal phase of the macaque menstrual cycle. J Clin Endocrinol Metab. 1991;72:326-362.

112 Brannian JD, Shiigi SM, Stouffer RL. Gonadotropin surge increases fluorescent-tagged low-density lipoprotein uptake by macaque granulosa cells from preovulatory follicles. Biol Reprod. 1992;47:355-360.

113 Rojas FJ, Moretti-Rojas I, Balmaceda JP, Asch RH. Regulation of gonadotropin-stimulable adenylyl cyclase of the primate corpus luteum. J Steroid Biochem. 1989;32:175-182.

114 McLachlan RI, Cohen NL, Vale WW, et al. The importance of luteinizing hormone in the control of inhibin and progesterone secretion by the human corpus luteum. J Clin Endocrinol Metab. 1989;68:1078-1085.

115 Molskness TA, Woodruff TK, Hess DL, et al. Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys. J Clin Endocrinol Metab. 1996;81:4002-4006.

116 le Nestour E, Marraoui J, Lahlou N, et al. Role of estradiol in the rise in follicle-stimulating hormone levels during the luteal-follicular transition. J Clin Endocrinol Metab. 1993;77:439-442.

117 Christin-Maitre S, Taylor AE, Khoury RH, et al. Homologous in vitro bioassay for follicle-stimulating hormone (FSH) reveals increased FSH biological signal during the mid- to late luteal phase of the human menstrual cycle. J Clin Endocrinol Metab. 1996;81:2080-2088.

118 Roseff SJ, Bangah ML, Kettel LM, et al. Dynamic changes in circulating inhibin levels during the luteal-follicular transition of the human menstrual cycle. J Clin Endocrinol Metab. 1989;69:1033-1039.

119 Muttukrishna S, Fowler PA, George L, et al. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab. 1996;81:3328-3334.

120 Shikone T, Yamoto M, Kokawa K, et al. Apoptosis of human corpora lutea during cyclic luteal regression and early pregnancy. J Clin Endocrinol Metab. 1996;81:2376-2380.

121 Young KA, Hennebold JD, Stouffer RL. Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. Mol Hum Reprod. 2002;8:833-840.

122 Friden BE, Runesson E, Hahlin M, Brannstrom M. Evidence for nitric oxide acting as a luteolytic factor in the human corpus luteum. Mol Hum Reprod. 2000;6:397-403.

123 Vega M, Urrutia L, Iniguez G, et al. Nitric oxide induces apoptosis in the human corpus luteum in vitro. Mol Hum Reprod. 2000;6:681-687.